Menstrual migraine: Timing is everything

Neurology

Volumn 63, Issue 2, 2004, Pages 202-203

  Loder, Elizabeth ^a  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; FROVATRIPTAN; PLACEBO; SEROTONIN 1 AGONIST;

ADULT; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; EDITORIAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MIGRAINE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 3242764486     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000134523.39673.2D     Document Type: Editorial

References (7)

1. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351-353.
2. Silberstein S, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-269.
3. Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517-1523.
4. International Classification of Headache Disorders. Cephalalgia 2004;24(suppl 1):1-160.
5. Martin V. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229-237.
6. Newman L, Mannix LK, Landy S, et al. A double-blind, randomized, placebo-controlled trial of naratriptan in the prophylaxis of menstrual migraine. Headache 2001;41:248-256.
7. Dowson A, Brandes J, Loftus J, et al. Naratriptan as intermittent prophylaxis for menstrually associated migraine (MAM): a review of efficacy and tolerability. Eur J Neurol 2003;10(suppl 1):73. Abstract.